Ignite Creation Date:
2024-05-06 @ 6:40 PM
Last Modification Date:
2024-10-26 @ 2:52 PM
Study NCT ID:
NCT05745545
Status:
RECRUITING
Last Update Posted:
2023-02-28
First Post:
2023-02-16
Brief Title:
Clinical Trial of COVID-19 VaccineSARS-CoV-2 VariantOmicron BA5 mRNA Vaccine in Participants Aged 18 Years and Over
Sponsor:
AIM Vaccine Co Ltd
Organization:
AIM Vaccine Co Ltd
Study Overview
Official Title:
A Single-center Randomized Blinded Placebo-controlled Clinical Trial to Evaluate the Protective Efficacy Safety and Immunogenicity of One Dose of the SARS-CoV-2 Variant Omicron BA5 mRNA Vaccine in People Aged 18 Years and Older Who Had Received Two or Three Doses of Inactivated COVID-19 Vaccine
Status:
RECRUITING
Status Verified Date:
2022-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center randomized blinded placebo-controlled clinical trial to evaluate the protective efficacy safety and immunogenicity of one dose of the SARS-CoV-2 variant Omicron BA5 mRNA vaccine in people aged 18 years and older who had received two or three doses of inactivated COVID-19 vaccine
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None